Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious ( absolute excess as compared with placebo , @ percentage points ; P < @ ) and with an increased incidence of diabetes diagnoses ( absolute excess , @ percentage points ; P < @ ) , as well as increases in serious adverse events associated with the gastrointestinal system ( absolute excess , @ percentage point ; P < @ ) , musculoskeletal system ( absolute excess , @ percentage points ; P < @ ) , skin ( absolute excess , @ percentage points ; P = @ ) , and unexpectedly , infection ( absolute excess , @ percentage points ; P < @ ) and bleeding ( absolute excess , @ percentage points ; P < @ ) .